Abstract: A semiconductor package including a first semiconductor die, a second semiconductor die, a first insulating encapsulation, a dielectric layer structure, a conductor structure and a second insulating encapsulation is provided. The first semiconductor die includes a first semiconductor substrate and a through silicon via (TSV) extending from a first side to a second side of the semiconductor substrate. The second semiconductor die is disposed on the first side of the semiconductor substrate. The first insulating encapsulation on the second semiconductor die encapsulates the first semiconductor die. A terminal of the TSV is coplanar with a surface of the first insulating encapsulation. The dielectric layer structure covers the first semiconductor die and the first insulating encapsulation. The conductor structure extends through the dielectric layer structure and contacts with the through silicon via.

Abstract: The present disclosure provides a thin film including a first thermoplastic polyolefin (TPO) elastomer which is anhydride-grafted. The present disclosure further provides a method for manufacturing the thin film, a laminated material and a method for adhesion.

Abstract: A back cover assembly of an electronic mobile device capable of controlling light emission effect comprises a back cover combinable to an electronic mobile device; the back cover including a flash hole positioned to be corresponding to a light emitting device of the electronic mobile device; the flash hole causing light emitting from the electronic mobile device to emit outwards; and at least one light guide strip on a light guide area or on a periphery of the back cover for guiding light to the whole light guide area The light guide strip includes a flash contact section which serves to contact the light emitting from the flashlight from the electronic mobile device. The flash contact section is separable from other portion of the light guide strip. A light control unit serves for controlling separation or combination of the flash contact section with other portion of the light guide strip.

Abstract: The invention discloses a method for forming granular polynary nano compound, which comprises the steps of (S1) mixing at least two materials, selected from a pre-determined group, to contact it with a aliphatic amine to form a mixture; (S2) inputting a noble gas to the housing that the mixture disposed; (S3) heating the mixture to a first temperature and maintain at the first temperature for a first period; (S4) heating the mixture to the second temperature by a pre-determined heating rate and maintain at the second temperature for a second period; and (S5) precipitating the granular polynary nano compound from the mixture by a pre-determined way.

Abstract: Modified oligonucleotides having a conserved G4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus are provided. G4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for viral-associated diseases are also provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of Tudor-SN. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Tudor-SN. Methods of using these compounds for modulation of Tudor-SN expression and for diagnosis and treatment of diseases and conditions associated with expression of Tudor-SN are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of Tudor-SN. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Tudor-SN. Methods of using these compounds for modulation of Tudor-SN expression and for diagnosis and treatment of diseases and conditions associated with expression of Tudor-SN are provided.

Abstract: Modified oligonucleotides having a conserved G4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus or phospholipase A2 or to modulate the telomere length of a chromosome are provided. G4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for viral-associated diseases and diseases associated with elevated levels of phospholipase A2 are also provided. Methods of modulating telomere length of a chromosome are also provided; modulation of telomere length is believed to play a role in the aging process of a cell and in control of malignant cell growth.

Abstract: Modified oligonucleotides having a GGG motif sequence and a sufficient number of flanking nucleotides to modulate the telomere length of a chromosome are provided. Methods of modulating telomere length of a mammalian chromosome in vitro and in vivo are also provided, as are methods for inhibiting the division of a malignant mammalian cell and for modulating the effects of cellular aging.

Abstract: Compounds, compositions and methods are provided for modulating the expression of Interleukin 12 p35 subunit. The compositions comprise chemically modified antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Interleukin 12 p35 subunit. Methods of using these compounds for modulation of Interleukin 12 p35 subunit expression and for treatment of diseases associated with expression of Interleukin 12 p35 subunit are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G protein-coupled receptor kinase 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G protein-coupled receptor kinase 6. Methods of using these compounds for modulation of G protein-coupled receptor kinase 6 expression and for treatment of diseases associated with expression of G protein-coupled receptor kinase 6 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of DR1-associated protein 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding DR1-associated protein 1. Methods of using these compounds for modulation of DR1-associated protein 1 expression and for diagnosis and treatment of disease associated with expression of DR1-associated protein 1 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of nidogen. The compositions comprise oligonucleotides, targeted to nucleic acid encoding nidogen. Methods of using these compounds for modulation of nidogen expression and for diagnosis and treatment of disease associated with expression of nidogen are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of FBP-interacting repressor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding FBP-interacting repressor. Methods of using these compounds for modulation of FBP-interacting repressor expression and for diagnosis and treatment of disease associated with expression of FBP-interacting repressor are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of G protein-coupled receptor RE2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding G protein-coupled receptor RE2. Methods of using these compounds for modulation of G protein-coupled receptor RE2 expression and for diagnosis and treatment of disease associated with expression of G protein-coupled receptor RE2 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of KIAA1531 protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding KIAA1531 protein. Methods of using these compounds for modulation of KIAA1531 protein expression and for treatment of diseases associated with expression of KIAA1531 protein are provided.

Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human mdm2. The compositions include antisense compounds targeted to nucleic acids encoding mdm2. Methods of using these oligonucleotides for inhibition of mdm2 expression and for treatment of diseases such as cancers associated with overexpression of mdm2 are provided.

Abstract: Modified oligonucleotides having a GGG motif sequence and a sufficient number of flanking nucleotides to modulate the telomere length of a chromosome are provided. Methods of modulating telomere length of a mammalian chromosome in vitro and in vivo are also provided, as are methods for inhibiting the division of a malignant mammalian cell and for modulating the effects of cellular aging.

Abstract: Modified oligonucleotides having a conserved G.sub.4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus such as HSV-1 or phospholipase A.sub.2 or to modulate the telomere length of a chromosome are provided. G.sub.4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnosis and therapeutics for viral-associated diseases and diseases associated with elevated levels of phospholipase A.sub.2 are also provided. Methods of modulating telomere length of a chromosome are also provided; modulation of telomere length is believed to plat a role in the aging process of a cell and in control of malignant cell growth.